ABBV · Company research
ABBVIE INC. (ABBV): Stock News & Events
Recent company-linked news records available in the database.
RESEARCH CONTEXT
Understand the numbers
Recent company-linked news records available in the database. Use period, currency, units and source fields when interpreting values.
78records availableHealthcare
Stock News & Events data
Database-backed records only
| title | summary | url | source | published at | sentiment | sentiment score | relevance score |
|---|---|---|---|---|---|---|---|
| Kevin Warsh's Fed May Not Cut Rates Soon. That's Why This Dividend Stock Belongs in Your Portfolio. | With the Federal Reserve likely to maintain or raise interest rates through the end of 2026, dividend stocks like AbbVie are positioned to perform well. AbbVie, a pharmaceutical company with over 50 years of dividend increases, offers resilience in a high-rate environment due to its strong balance sheet, fixed-rate debt, and non-rate-sensitive business model. | View source ↗ | The Motley Fool | Oct 20, 2026 | bullish | 0.333 | 1 |
| Migraine Market is Expected to Expand at 6% Growth Rate by 2036, Owing to the Development of Novel Mechanisms beyond CGRP, including PACAP-targeted Therapies, TRPA1 Antagonists, and Next-generation Neuromuscular Approaches | DelveInsight | The global migraine market is projected to grow at a 6% CAGR through 2036, reaching expansion driven by rising prevalence, improved diagnosis rates, and development of novel therapies beyond CGRP inhibitors. Key emerging treatments include PACAP-targeted therapies, TRPA1 antagonists, and next-generation neuromuscular approaches. The market was valued at USD 8.3 billion in 2025 across seven major markets, with the United States leading. | View source ↗ | GlobeNewswire Inc. | Oct 19, 2026 | bullish | 1 | 1 |
| Pfizer's Non-Oncology Performance in Q3: Driving Factors to Watch | Pfizer will report Q3 2026 earnings on November 3, with focus on non-oncology segments. Eliquis demand is expected to boost Primary Care sales, while COVID-19 vaccine and Paxlovid revenues will decline. Specialty Care segment may see Vyndaqel growth offset by declines in Xeljanz and Enbrel due to competitive pressures. | View source ↗ | Zacks Investment Research | Oct 19, 2026 | bullish | 0.167 | 1 |
| Zacks Market Edge Highlights: Palantir Technologies, BP, Palo Alto Networks, Visa and AbbVie | Zacks Market Edge podcast episode #503 features five stock picks for investors seeking opportunities amid market volatility. The selections span growth stocks (Palantir, Palo Alto Networks), value plays (BP), consistent performers (Visa), and pharmaceuticals (AbbVie), offering diverse investment strategies across different market conditions. | View source ↗ | Zacks Investment Research | Oct 19, 2026 | bullish | 0.8 | 1 |
| AbbVie's Neuroscience Franchise: What to Expect Ahead of Q3 Results | AbbVie's neuroscience revenues are projected to reach $3.29 billion in Q3 2026, representing approximately 16% year-over-year growth. Key contributors include established drugs Vraylar ($1.08B) and Botox Therapeutic ($1.07B), along with newer products like Vyalev ($283M) and the recently FDA-approved Juvmo. The company faces competition from Biogen and Johnson & Johnson in the neuroscience market. | View source ↗ | Zacks Investment Research | Oct 19, 2026 | bullish | 0.333 | 1 |
| Warren Buffett's Bluntest Warning Yet -- and 3 Stocks Built to Survive It | Warren Buffett warns that investors are in an excessive gambling mood, engaging in risky short-term options trading rather than long-term investing. Despite market volatility concerns, pharmaceutical and biotech stocks like Vertex Pharmaceuticals, Eli Lilly, and AbbVie are positioned to weather economic downturns due to consistent demand for their treatments. | View source ↗ | The Motley Fool | Oct 19, 2026 | bullish | 0.6 | 1 |
| Forget High-Yield Traps: AbbVie Is the Dividend King to Buy and Hold Through Any Rate Cycle | AbbVie is positioned as a reliable dividend stock that avoids high-yield trap characteristics. With 54 consecutive years of dividend increases, strong free cash flow generation, fixed-rate debt, and blockbuster drugs Skyrizi and Rinvoq generating over $7.5 billion quarterly, AbbVie maintains Dividend King status regardless of interest rate cycles. The company's robust pipeline of 90 clinical programs provides future revenue stability. | View source ↗ | The Motley Fool | Oct 17, 2026 | bullish | 0.5 | 1 |
| Here's How Many Shares of AbbVie You'd Need for $5,000 in Yearly Dividends | AbbVie, a Dividend King with 53 consecutive years of dividend increases, would require 723 shares (approximately $206,358) to generate $5,000 in annual dividends at its current price. Despite a modest 2.4% forward yield, the pharmaceutical giant's strong portfolio of blockbuster drugs, low P/E ratio of 16, and 93% stock rally over three years make it an attractive long-term income investment, even compared to higher-yielding alternatives like Pfizer. | View source ↗ | The Motley Fool | Oct 16, 2026 | neutral | 0 | 1 |
| 5 Stock Ideas for Your Short List | Zacks stock strategist Tracey Ryniec highlights five stocks breaking out to new highs despite October market volatility. The picks span growth and value categories: Palantir Technologies (strong revenue growth but expensive valuation), BP (cheap energy play with high dividend yield), Palo Alto Networks (cybersecurity leader with consistent earnings), Visa (payments leader with perfect earnings track record), and AbbVie (pharma company with growth potential but recent estimate cuts). | View source ↗ | Zacks Investment Research | Oct 16, 2026 | bullish | 0.8 | 1 |
| Breaking Down The Big 3 Investing Strategies | The article explains three primary investment strategies: income investing focuses on dividend-paying stocks and regular payouts; growth investing targets companies with above-average earnings and revenue growth, often at premium valuations; and value investing seeks undervalued stocks trading below their intrinsic value. Each strategy caters to different investor profiles and risk tolerances. | View source ↗ | Zacks Investment Research | Oct 15, 2026 | bullish | 1 | 1 |
| Breaking Down The Big 3 Investing Strategies | The article explains three primary investment strategies: income investing focuses on dividend-paying stocks and regular payouts; growth investing targets companies with above-average earnings and revenue growth, often at premium valuations; and value investing seeks undervalued stocks trading below their intrinsic value. Each strategy caters to different investor profiles and risk tolerances. | View source ↗ | Zacks Investment Research | Oct 15, 2026 | bullish | 1 | 1 |
| The Dividend Divide: Pure Dividend Strategy ETF Meets Tech-Driven Growth ETF | iShares Core High Dividend ETF (HDV) and Fidelity High Dividend ETF (FDVV) offer contrasting approaches to dividend investing. HDV emphasizes defensive sectors like energy and staples with lower volatility and a 0.08% expense ratio, while FDVV incorporates tech exposure with higher growth potential but greater volatility and a 0.15% expense ratio. HDV has delivered 12.8% CAGR since 2021 with a 2.9% yield, while FDVV achieved 13.5% CAGR with a 2.8% yield. The choice depends on whether investors prioritize conservative income or growth-oriented dividend strategies. | View source ↗ | The Motley Fool | Oct 15, 2026 | bullish | 0.286 | 1 |
| The Dividend Divide: Pure Dividend Strategy ETF Meets Tech-Driven Growth ETF | iShares Core High Dividend ETF (HDV) and Fidelity High Dividend ETF (FDVV) offer contrasting approaches to dividend investing. HDV emphasizes defensive sectors like energy and staples with lower volatility and a 0.08% expense ratio, while FDVV incorporates tech exposure with higher growth potential but greater volatility and a 0.15% expense ratio. HDV has delivered 12.8% CAGR since 2021 with a 2.9% yield, while FDVV achieved 13.5% CAGR with a 2.8% yield. The choice depends on whether investors prioritize conservative income or growth-oriented dividend strategies. | View source ↗ | The Motley Fool | Oct 15, 2026 | bullish | 0.286 | 1 |
| The Dividend Divide: Pure Dividend Strategy ETF Meets Tech-Driven Growth ETF | iShares Core High Dividend ETF (HDV) and Fidelity High Dividend ETF (FDVV) offer contrasting approaches to dividend investing. HDV emphasizes defensive sectors like energy and staples with lower volatility and a 0.08% expense ratio, while FDVV incorporates tech exposure with higher growth potential but greater volatility and a 0.15% expense ratio. HDV has delivered 12.8% CAGR since 2021 with a 2.9% yield, while FDVV achieved 13.5% CAGR with a 2.8% yield. The choice depends on whether investors prioritize conservative income or growth-oriented dividend strategies. | View source ↗ | The Motley Fool | Oct 15, 2026 | bullish | 0.286 | 1 |
| Obesity Clinical Trial and Competitive Landscape Surges as 200+ Companies Advance Next-Generation Therapies | DelveInsight | Over 200 companies are advancing next-generation obesity therapies, with more than 30 drugs in late-stage development and 180+ in mid and early stages. Key players include Eli Lilly, Novo Nordisk, Viking Therapeutics, and Roche, developing innovative mechanisms like dual GLP-1/GIP receptor agonists and triple hormone receptor agonists. Recent approvals include Novo Nordisk's oral Wegovy formulation and Eli Lilly's orforglipron, while multiple Phase III trials show promising weight loss results. | View source ↗ | GlobeNewswire Inc. | Oct 15, 2026 | bullish | 0.875 | 1 |
| Obesity Clinical Trial and Competitive Landscape Surges as 200+ Companies Advance Next-Generation Therapies | DelveInsight | Over 200 companies are advancing next-generation obesity therapies, with more than 30 drugs in late-stage development and 180+ in mid and early stages. Key players include Eli Lilly, Novo Nordisk, Viking Therapeutics, and Roche, developing innovative mechanisms like dual GLP-1/GIP receptor agonists and triple hormone receptor agonists. Recent approvals include Novo Nordisk's oral Wegovy formulation and Eli Lilly's orforglipron, while multiple Phase III trials show promising weight loss results. | View source ↗ | GlobeNewswire Inc. | Oct 15, 2026 | bullish | 0.875 | 1 |
| Obesity Clinical Trial and Competitive Landscape Surges as 200+ Companies Advance Next-Generation Therapies | DelveInsight | Over 200 companies are advancing next-generation obesity therapies, with more than 30 drugs in late-stage development and 180+ in mid and early stages. Key players include Eli Lilly, Novo Nordisk, Viking Therapeutics, and Roche, developing innovative mechanisms like dual GLP-1/GIP receptor agonists and triple hormone receptor agonists. Recent approvals include Novo Nordisk's oral Wegovy formulation and Eli Lilly's orforglipron, while multiple Phase III trials show promising weight loss results. | View source ↗ | GlobeNewswire Inc. | Oct 15, 2026 | bullish | 0.875 | 1 |
| AbbVie vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026? | AbbVie and Pfizer are compared as healthcare investment options in 2026. AbbVie has successfully navigated patent cliff challenges with strong growth from Skyrizi and Rinvoq offsetting Humira losses, while Pfizer is rebuilding its pipeline around obesity drugs and awaiting key pipeline readouts. The article recommends AbbVie as the clearer choice for investors seeking current pharmaceutical exposure, though both companies face biosimilar competition and regulatory pressures. | View source ↗ | The Motley Fool | Oct 15, 2026 | bullish | 0.2 | 1 |
| AbbVie vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026? | AbbVie and Pfizer are compared as healthcare investment options in 2026. AbbVie has successfully navigated patent cliff challenges with strong growth from Skyrizi and Rinvoq offsetting Humira losses, while Pfizer is rebuilding its pipeline around obesity drugs and awaiting key pipeline readouts. The article recommends AbbVie as the clearer choice for investors seeking current pharmaceutical exposure, though both companies face biosimilar competition and regulatory pressures. | View source ↗ | The Motley Fool | Oct 15, 2026 | bullish | 0.2 | 1 |
| AbbVie vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026? | AbbVie and Pfizer are compared as healthcare investment options in 2026. AbbVie has successfully navigated patent cliff challenges with strong growth from Skyrizi and Rinvoq offsetting Humira losses, while Pfizer is rebuilding its pipeline around obesity drugs and awaiting key pipeline readouts. The article recommends AbbVie as the clearer choice for investors seeking current pharmaceutical exposure, though both companies face biosimilar competition and regulatory pressures. | View source ↗ | The Motley Fool | Oct 15, 2026 | bullish | 0.2 | 1 |
| Here's How Much a $1000 Investment in Halozyme Therapeutics Made 10 Years Ago Would Be Worth Today | A $1,000 investment in Halozyme Therapeutics (HALO) made in October 2016 would be worth $11,612.33 as of October 15, 2026, representing a 1,061.23% gain. This significantly outperformed the S&P 500's 261.89% return over the same period. The biopharmaceutical company's success is driven by royalties from its ENHANZE drug delivery technology licensed to major pharma partners, though it faces headwinds from biosimilar competition on blockbuster drugs. | View source ↗ | Zacks Investment Research | Oct 15, 2026 | neutral | 0.111 | 1 |
| Here's How Much a $1000 Investment in Halozyme Therapeutics Made 10 Years Ago Would Be Worth Today | A $1,000 investment in Halozyme Therapeutics (HALO) made in October 2016 would be worth $11,612.33 as of October 15, 2026, representing a 1,061.23% gain. This significantly outperformed the S&P 500's 261.89% return over the same period. The biopharmaceutical company's success is driven by royalties from its ENHANZE drug delivery technology licensed to major pharma partners, though it faces headwinds from biosimilar competition on blockbuster drugs. | View source ↗ | Zacks Investment Research | Oct 15, 2026 | neutral | 0.111 | 1 |
| Is First Trust NASDAQ Pharmaceuticals ETF (FTXH) a Strong ETF Right Now? | The First Trust NASDAQ Pharmaceuticals ETF (FTXH) is a smart beta ETF with $1.07 billion in assets that tracks the Nasdaq US Smart Pharmaceuticals Index. With a 0.60% expense ratio and 51 holdings, it has delivered strong performance of 25.84% year-to-date and 43.75% over the past year as of October 15, 2026. However, investors should consider alternative pharmaceutical ETFs like VanEck Pharmaceutical ETF (PPH) and iShares U.S. Pharmaceuticals ETF (IHE), which offer lower expense ratios. | View source ↗ | Zacks Investment Research | Oct 15, 2026 | bullish | 0.5 | 1 |
| Is First Trust NASDAQ Pharmaceuticals ETF (FTXH) a Strong ETF Right Now? | The First Trust NASDAQ Pharmaceuticals ETF (FTXH) is a smart beta ETF with $1.07 billion in assets that tracks the Nasdaq US Smart Pharmaceuticals Index. With a 0.60% expense ratio and 51 holdings, it has delivered strong performance of 25.84% year-to-date and 43.75% over the past year as of October 15, 2026. However, investors should consider alternative pharmaceutical ETFs like VanEck Pharmaceutical ETF (PPH) and iShares U.S. Pharmaceuticals ETF (IHE), which offer lower expense ratios. | View source ↗ | Zacks Investment Research | Oct 15, 2026 | bullish | 0.5 | 1 |
| AbbVie Inc Stock (ABBV) Moved Up by 3.36% on Oct 14: A Full Analysis - TradingKey | AbbVie Inc Stock (ABBV) Moved Up by 3.36% on Oct 14: A Full Analysis TradingKey | View source ↗ | TradingKey | Oct 14, 2026 | neutral | 0 | 0.6 |
| Which Pharma Stock Looks More Attractive: Sanofi or AbbVie? - Yahoo Finance | Which Pharma Stock Looks More Attractive: Sanofi or AbbVie? Yahoo Finance | View source ↗ | Yahoo Finance | Oct 14, 2026 | neutral | 0 | 0.6 |
| Which Pharma Stock Looks More Attractive: Sanofi or AbbVie? | Sanofi and AbbVie are compared as major pharmaceutical companies with different growth drivers. Sanofi, powered by Dupixent's strong performance and newer medicines, trades at a lower valuation (7.82x forward earnings) with a 4.5% dividend yield, while AbbVie relies on Skyrizi and Rinvoq to offset Humira's decline but trades at 19.62x forward earnings with a 2.5% yield. Analysts favor Sanofi (Zacks Rank #3 Hold) over AbbVie (Rank #4 Sell) due to its attractive valuation and upgraded growth outlook. | View source ↗ | Zacks Investment Research | Oct 14, 2026 | neutral | 0 | 1 |
| AbbVie Inc. (ABBV) is Attracting Investor Attention: Here is What You Should Know | AbbVie has recently attracted investor attention with shares returning +4.3% over the past month, outperforming the S&P 500's +2.1% gain. However, despite strong earnings growth expectations (+104.3% YoY for current quarter) and consistent beats on both EPS and revenue estimates, the company received a Zacks Rank #4 (Sell) rating due to recent downward revisions in consensus earnings estimates. The stock is valued at par with peers (C grade) but may underperform the broader market in the near term. | View source ↗ | Zacks Investment Research | Oct 14, 2026 | bearish | -1 | 1 |
| AbbVie Inc. (ABBV) is Attracting Investor Attention: Here is What You Should Know | AbbVie has recently attracted investor attention with shares returning +4.3% over the past month, outperforming the S&P 500's +2.1% gain. However, despite strong earnings growth expectations (+104.3% YoY for current quarter) and consistent beats on both EPS and revenue estimates, the company received a Zacks Rank #4 (Sell) rating due to recent downward revisions in consensus earnings estimates. The stock is valued at par with peers (C grade) but may underperform the broader market in the near term. | View source ↗ | Zacks Investment Research | Oct 14, 2026 | bearish | -1 | 1 |
| By week 12, 27.7% of Crohn’s patients taking AbbVie’s SKYRIZI had little to no gut inflammation, vs. 10.2% on placebo. - Stock Titan | By week 12, 27.7% of Crohn’s patients taking AbbVie’s SKYRIZI had little to no gut inflammation, vs. 10.2% on placebo. Stock Titan | View source ↗ | Stock Titan | Oct 13, 2026 | neutral | 0 | 0.6 |
| ABBV Stock Gains 1.68%, RSI Overbought: Explained - JournalArta | ABBV Stock Gains 1.68%, RSI Overbought: Explained JournalArta | View source ↗ | JournalArta | Oct 13, 2026 | neutral | 0 | 0.6 |
| AbbVie (ABBV) Rises As Market Takes a Dip: Key Facts | AbbVie (ABBV) rose 1.65% to $281.04, outperforming the S&P 500's decline. The stock has gained 7.53% over the past month and is expected to report earnings on October 30, 2026, with projected EPS growth of 104.3% and revenue growth of 10.01%. However, the company carries a Zacks Rank #4 (Sell) rating, trades at a premium Forward P/E of 19.77 versus its industry average of 16.16, and consensus EPS estimates have declined 0.79% over the last 30 days. | View source ↗ | Zacks Investment Research | Oct 12, 2026 | bearish | -1 | 1 |
| ABBV 261016 262.50C (ABBV261016C262500) Stock Options Chain | Quotes & News - Moomoo | ABBV 261016 262.50C (ABBV261016C262500) Stock Options Chain | Quotes & News Moomoo | View source ↗ | Moomoo | Oct 12, 2026 | neutral | 0 | 0.6 |
| AbbVie (ABBV) Highlights Promising IBD Data at ACG 2026 Amid Div - GuruFocus | AbbVie (ABBV) Highlights Promising IBD Data at ACG 2026 Amid Div GuruFocus | View source ↗ | GuruFocus | Oct 11, 2026 | neutral | 0 | 0.6 |
| AbbVie (ABBV) Wins Two FDA Breakthrough Tags, Is The Stock Fully Priced? - Simply Wall Street | AbbVie (ABBV) Wins Two FDA Breakthrough Tags, Is The Stock Fully Priced? Simply Wall Street | View source ↗ | Simply Wall Street | Oct 11, 2026 | neutral | 0 | 0.6 |
| 93.3% of Crohn’s patients with fistulas who stayed on AbbVie’s RINVOQ reached clinical and steroid-free remission. - Stock Titan | 93.3% of Crohn’s patients with fistulas who stayed on AbbVie’s RINVOQ reached clinical and steroid-free remission. Stock Titan | View source ↗ | Stock Titan | Oct 11, 2026 | neutral | 0 | 0.6 |
| Here’s How Much You Would Have Made Owning AbbVie Stock In The Last 5 Years - Benzinga | Here’s How Much You Would Have Made Owning AbbVie Stock In The Last 5 Years Benzinga | View source ↗ | Benzinga | Oct 9, 2026 | neutral | 0 | 0.6 |
| A Stock Market Crash Is Coming By the End of 2027, According to Some Economists. Here Are 2 Stocks to Buy Before That Happens | Some economists predict a market downturn and recession by end of 2027. The article recommends two pharmaceutical stocks—AbbVie and Amgen—as defensive investments that have historically weathered downturns well due to their diversified drug portfolios, consistent revenue from chronic disease treatments, strong pipelines, and reliable dividend payments. | View source ↗ | The Motley Fool | Oct 9, 2026 | bullish | 0.667 | 1 |
| A Stock Market Crash Is Coming By the End of 2027, According to Some Economists. Here Are 2 Stocks to Buy Before That Happens | Some economists predict a market downturn and recession by end of 2027. The article recommends two pharmaceutical stocks—AbbVie and Amgen—as defensive investments that have historically weathered downturns well due to their diversified drug portfolios, consistent revenue from chronic disease treatments, strong pipelines, and reliable dividend payments. | View source ↗ | The Motley Fool | Oct 9, 2026 | bullish | 0.667 | 1 |
| Cancer Stocks to Consider as Oncology Innovation Accelerates | The global oncology market is experiencing rapid growth due to rising cancer incidence, aging populations, and medical advances including immunotherapies, targeted medicines, and personalized vaccines. Major pharmaceutical companies are investing heavily in oncology R&D, with innovations in antibody-drug conjugates, bispecific antibodies, and next-generation immunotherapies. Three companies highlighted for oncology exposure are Pfizer, Merit Medical Systems, and Abbott Laboratories. | View source ↗ | Zacks Investment Research | Oct 9, 2026 | bullish | 1 | 1 |
| Cancer Stocks to Consider as Oncology Innovation Accelerates | The global oncology market is experiencing rapid growth due to rising cancer incidence, aging populations, and medical advances including immunotherapies, targeted medicines, and personalized vaccines. Major pharmaceutical companies are investing heavily in oncology R&D, with innovations in antibody-drug conjugates, bispecific antibodies, and next-generation immunotherapies. Three companies highlighted for oncology exposure are Pfizer, Merit Medical Systems, and Abbott Laboratories. | View source ↗ | Zacks Investment Research | Oct 9, 2026 | bullish | 1 | 1 |
| AbbVie's Temab-A Gets Two FDA Breakthrough Therapy Tags in Cancer | AbbVie announced that its investigational antibody-drug conjugate Temab-A (telisotuzumab adizutecan) has received two FDA Breakthrough Therapy designations for colorectal cancer and non-small cell lung cancer. The designations were based on data from the M21-404 study, and the company is evaluating Temab-A across multiple advanced solid tumors as part of its expanding oncology pipeline. | View source ↗ | Zacks Investment Research | Oct 8, 2026 | bullish | 0.4 | 1 |
| AbbVie's Temab-A Gets Two FDA Breakthrough Therapy Tags in Cancer | AbbVie announced that its investigational antibody-drug conjugate Temab-A (telisotuzumab adizutecan) has received two FDA Breakthrough Therapy designations for colorectal cancer and non-small cell lung cancer. The designations were based on data from the M21-404 study, and the company is evaluating Temab-A across multiple advanced solid tumors as part of its expanding oncology pipeline. | View source ↗ | Zacks Investment Research | Oct 8, 2026 | bullish | 0.4 | 1 |
| AbbVie's Temab-A Gets Two FDA Breakthrough Therapy Tags in Cancer | AbbVie announced that its investigational antibody-drug conjugate Temab-A (telisotuzumab adizutecan) has received two FDA Breakthrough Therapy designations for colorectal cancer and non-small cell lung cancer. The designations were based on data from the M21-404 study, and the company is evaluating Temab-A across multiple advanced solid tumors as part of its expanding oncology pipeline. | View source ↗ | Zacks Investment Research | Oct 8, 2026 | bullish | 0.4 | 1 |
| AbbVie Shares Rise After Hours on FDA Designations - AbbVie (NYSE:ABBV) - Benzinga | AbbVie Shares Rise After Hours on FDA Designations - AbbVie (NYSE:ABBV) Benzinga | View source ↗ | Benzinga | Oct 8, 2026 | neutral | 0 | 0.6 |
| Will Linzess Continue to Aid Ironwood's Top-Line Growth in Q3? | Ironwood Pharmaceuticals (IRWD) is experiencing strong prescription demand for its primary product Linzess, with U.S. net profit share surging 72.6% year-over-year in the first half of 2026. The company raised its full-year 2026 revenue guidance to $460-$485 million, citing continued momentum from Linzess sales, recent FDA label expansion for pediatric patients, and favorable pricing dynamics. IRWD stock is trading at a valuation discount to the industry and carries a Zacks Rank #2 (Buy) rating. | View source ↗ | Zacks Investment Research | Oct 7, 2026 | bullish | 0.25 | 1 |
| Will Linzess Continue to Aid Ironwood's Top-Line Growth in Q3? | Ironwood Pharmaceuticals (IRWD) is experiencing strong prescription demand for its primary product Linzess, with U.S. net profit share surging 72.6% year-over-year in the first half of 2026. The company raised its full-year 2026 revenue guidance to $460-$485 million, citing continued momentum from Linzess sales, recent FDA label expansion for pediatric patients, and favorable pricing dynamics. IRWD stock is trading at a valuation discount to the industry and carries a Zacks Rank #2 (Buy) rating. | View source ↗ | Zacks Investment Research | Oct 7, 2026 | bullish | 0.25 | 1 |
| AbbVie's Epcoritamab Combo Shows PFS Benefit in Frontline DLBCL | AbbVie and Genmab announced positive phase III EPCORE DLBCL-2 study results showing that epcoritamab combined with R-CHOP significantly improved progression-free survival compared to R-CHOP alone in newly diagnosed diffuse large B-cell lymphoma patients, reducing disease progression or death risk by 51%. The combination was well tolerated with a safety profile consistent with prior reports. | View source ↗ | Zacks Investment Research | Oct 6, 2026 | bullish | 0.667 | 1 |
| AbbVie's Epcoritamab Combo Shows PFS Benefit in Frontline DLBCL | AbbVie and Genmab announced positive phase III EPCORE DLBCL-2 study results showing that epcoritamab combined with R-CHOP significantly improved progression-free survival compared to R-CHOP alone in newly diagnosed diffuse large B-cell lymphoma patients, reducing disease progression or death risk by 51%. The combination was well tolerated with a safety profile consistent with prior reports. | View source ↗ | Zacks Investment Research | Oct 6, 2026 | bullish | 0.667 | 1 |
| Did Frontline Lymphoma Trial Success Just Shift AbbVie (ABBV) Stock Narrative? - Simply Wall Street | Did Frontline Lymphoma Trial Success Just Shift AbbVie (ABBV) Stock Narrative? Simply Wall Street | View source ↗ | Simply Wall Street | Oct 6, 2026 | neutral | 0 | 0.6 |
| IYH Beats IXJ on Returns While Global Fund Offers Higher Yield | iShares U.S. Healthcare ETF (IYH) outperformed its global counterpart (IXJ) with 28.8% one-year returns versus 22.5%, while IXJ offers higher dividend yield at 1.4%. Both funds have nearly identical expense ratios (0.37-0.38%) and low volatility, with choice depending on whether investors prefer domestic or international healthcare exposure. | View source ↗ | The Motley Fool | Oct 6, 2026 | bullish | 0.4 | 1 |
| IYH Beats IXJ on Returns While Global Fund Offers Higher Yield | iShares U.S. Healthcare ETF (IYH) outperformed its global counterpart (IXJ) with 28.8% one-year returns versus 22.5%, while IXJ offers higher dividend yield at 1.4%. Both funds have nearly identical expense ratios (0.37-0.38%) and low volatility, with choice depending on whether investors prefer domestic or international healthcare exposure. | View source ↗ | The Motley Fool | Oct 6, 2026 | bullish | 0.4 | 1 |
| Strength Seen in Genmab (GMAB): Can Its 10.7% Jump Turn into More Strength? | Genmab shares rallied 10.7% following positive phase III trial data for epcoritamab in combination with R-CHOP for newly diagnosed diffuse large B-cell lymphoma. The stock's consensus EPS estimate was revised 8.7% higher over the past 30 days, though earnings are expected to decline 43.1% year-over-year while revenues grow 15.7%. The stock carries a Zacks Rank #3 (Hold) rating. | View source ↗ | Zacks Investment Research | Oct 6, 2026 | bullish | 0.333 | 1 |
| Strength Seen in Genmab (GMAB): Can Its 10.7% Jump Turn into More Strength? | Genmab shares rallied 10.7% following positive phase III trial data for epcoritamab in combination with R-CHOP for newly diagnosed diffuse large B-cell lymphoma. The stock's consensus EPS estimate was revised 8.7% higher over the past 30 days, though earnings are expected to decline 43.1% year-over-year while revenues grow 15.7%. The stock carries a Zacks Rank #3 (Hold) rating. | View source ↗ | Zacks Investment Research | Oct 6, 2026 | bullish | 0.333 | 1 |
| A lymphoma drug combination cut the risk of worsening or death by 51% in a trial. - Stock Titan | A lymphoma drug combination cut the risk of worsening or death by 51% in a trial. Stock Titan | View source ↗ | Stock Titan | Oct 6, 2026 | neutral | 0 | 0.6 |
| Why AbbVie (ABBV) Outpaced the Stock Market Today | AbbVie (ABBV) closed at $265.85, outperforming the S&P 500 with a +1.15% daily gain. The pharmaceutical company is expected to report earnings of $3.85 per share on October 30, 2026, representing 106.99% year-over-year growth, with revenue projected at $17.36 billion. AbbVie currently holds a Zacks Rank #3 (Hold) rating with a Forward P/E of 18.71, trading at a premium to its industry average. | View source ↗ | Zacks Investment Research | Oct 5, 2026 | neutral | 0 | 1 |
| AbbVie Updates 2026 Adjusted EPS Guidance After Q3 Expense - Quiver Quantitative | AbbVie Updates 2026 Adjusted EPS Guidance After Q3 Expense Quiver Quantitative | View source ↗ | Quiver Quantitative | Oct 5, 2026 | neutral | 0 | 0.6 |
| Why I Think These Are the 2 Smartest Stocks to Buy With $5,000 in October | Despite recent Fed rate hikes and rising Treasury yields, the article recommends two blue chip dividend stocks: AbbVie, a Dividend King with 53 consecutive years of dividend increases and strong growth prospects from new drugs, and Medtronic, which is on track to become a Dividend King with 49 consecutive years of dividend hikes and improving operational performance after recent restructuring. | View source ↗ | The Motley Fool | Oct 5, 2026 | bullish | 1 | 1 |
| Genmab and AbbVie Announce Epcoritamab in Combination with R-CHOP Demonstrates Statistically Significant Improvement in Progression-Free Survival in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma | Genmab and AbbVie announced positive Phase 3 trial results for epcoritamab combined with R-CHOP in newly diagnosed diffuse large B-cell lymphoma (DLBCL) patients. The combination demonstrated a statistically significant 51% reduction in disease progression or death risk compared to R-CHOP alone, with a favorable safety profile. This marks the first Phase 3 study of a bispecific antibody combination to show significant improvement in progression-free survival in frontline DLBCL treatment. | View source ↗ | GlobeNewswire Inc. | Oct 5, 2026 | bullish | 1 | 1 |
| FDA Expands Eli Lilly's Blood Cancer Drug Label in First-Line Setting | Eli Lilly announced FDA approval for Jaypirca (pirtobrutinib) as a first-line treatment for previously untreated CLL/SLL patients without 17p deletion. The drug reduced disease progression or death risk by 80% versus chemoimmunotherapy in the phase III BRUIN CLL-313 study. Jaypirca sales grew 66% to $357 million in H1 2026, with the drug's non-covalent BTK inhibitor mechanism differentiating it from competitors like Brukinsa, Calquence, and Imbruvica. | View source ↗ | Zacks Investment Research | Oct 5, 2026 | bearish | -0.5 | 1 |
| Better Healthcare ETF: Vanguard's Broad VHT vs. the iShares Biotechnology-Focused IBB | The article compares two healthcare ETFs: Vanguard Health Care ETF (VHT) offers broad sector exposure with a low 0.09% expense ratio and 1.4% dividend yield, while iShares Biotechnology ETF (IBB) focuses on biotech with higher growth potential (49.8% 1-year return) but greater volatility and a 39.8% maximum drawdown. VHT is recommended for conservative investors seeking stability, while IBB suits high-risk growth investors. | View source ↗ | The Motley Fool | Oct 5, 2026 | bullish | 0.4 | 1 |
| AbbVie Inc. (ABBV) Stock Forecasts - Yahoo! Finance Canada | AbbVie Inc. (ABBV) Stock Forecasts Yahoo! Finance Canada | View source ↗ | Yahoo! Finance Canada | Oct 4, 2026 | neutral | 0 | 0.6 |
| Better Pharmaceuticals ETF: VanEck's PPH vs. Invesco PJP | VanEck Pharmaceutical ETF (PPH) offers lower costs (0.36% expense ratio) and higher dividend yield (2%), making it better for long-term buy-and-hold investors. Invesco Pharmaceuticals ETF (PJP) delivered stronger 1-year returns (41% vs 31%) with more balanced U.S.-focused holdings, but charges higher fees (0.58%) and offers lower yield (0.9%). | View source ↗ | The Motley Fool | Oct 3, 2026 | bullish | 0.25 | 1 |
| How to Create a Million-Dollar Stock Portfolio | The article examines successful long-term investors like Ronald Read, Anne Scheiber, and Grace Groner who built million-dollar portfolios by holding blue-chip stocks for 50+ years and reinvesting dividends. It highlights three stocks favored by these investors: Wells Fargo, Abbott Laboratories, and AbbVie, emphasizing the power of compounding and patience in wealth building. | View source ↗ | Zacks Investment Research | Oct 2, 2026 | bullish | 1 | 1 |
| Can ABBV's New Parkinson's Pill Strengthen Its Neuroscience Franchise? | AbbVie received FDA approval for Juvmo, a once-daily oral treatment for Parkinson's disease launching in October 2026. As the first selective D1/D5 dopamine receptor agonist usable as standalone or combination therapy, Juvmo expands AbbVie's PD portfolio alongside Vyalev and Duopa, with the three therapies expected to generate peak sales above $5 billion. The approval validates AbbVie's $8.7 billion Cerevel Therapeutics acquisition and strengthens its neuroscience segment, which grew 22% year-over-year. | View source ↗ | Zacks Investment Research | Oct 2, 2026 | bullish | 0.333 | 1 |
| Can ABBV's New Parkinson's Pill Strengthen Its Neuroscience Franchise? | AbbVie received FDA approval for Juvmo, a once-daily oral treatment for Parkinson's disease launching in October 2026. As the first selective D1/D5 dopamine receptor agonist usable as standalone or combination therapy, Juvmo expands AbbVie's PD portfolio alongside Vyalev and Duopa, with the three therapies expected to generate peak sales above $5 billion. The approval validates AbbVie's $8.7 billion Cerevel Therapeutics acquisition and strengthens its neuroscience segment, which grew 22% year-over-year. | View source ↗ | Zacks Investment Research | Oct 2, 2026 | bullish | 0.333 | 1 |
| AbbVie (ABBV) Stock May Be 41% Undervalued On FDA Approval - Simply Wall Street | AbbVie (ABBV) Stock May Be 41% Undervalued On FDA Approval Simply Wall Street | View source ↗ | Simply Wall Street | Oct 1, 2026 | neutral | 0 | 0.6 |
| ABBV Stock Rises 25% in 6 Months: Time to Buy, Hold or Sell? - The Globe and Mail | ABBV Stock Rises 25% in 6 Months: Time to Buy, Hold or Sell? The Globe and Mail | View source ↗ | The Globe and Mail | Oct 1, 2026 | neutral | 0 | 0.6 |
| AbbVie Inc. (ABBV) Is a Trending Stock: Facts to Know Before Betting on It | AbbVie is a trending stock with strong earnings growth expectations of +40.5% for the current fiscal year and +14.8% for next year. The company has consistently beaten consensus estimates over the trailing four quarters. However, with a Zacks Rank #3 (Hold) rating and a C valuation grade indicating it trades at par with peers, the stock is expected to perform in line with the broader market in the near term. | View source ↗ | Zacks Investment Research | Oct 1, 2026 | neutral | 0 | 1 |
| AbbVie Inc. (ABBV) Is a Trending Stock: Facts to Know Before Betting on It | AbbVie is a trending stock with strong earnings growth expectations of +40.5% for the current fiscal year and +14.8% for next year. The company has consistently beaten consensus estimates over the trailing four quarters. However, with a Zacks Rank #3 (Hold) rating and a C valuation grade indicating it trades at par with peers, the stock is expected to perform in line with the broader market in the near term. | View source ↗ | Zacks Investment Research | Oct 1, 2026 | neutral | 0 | 1 |
| ABBV Stock Rises 25% in 6 Months: Time to Buy, Hold or Sell? | AbbVie's stock has gained 25.4% over six months, driven by strong growth from Skyrizi and Rinvoq, which are expected to generate over $31 billion in combined 2026 sales. The company is successfully navigating Humira's patent expiry through new immunology and neuroscience products. However, challenges include Humira biosimilar erosion, slowing oncology sales, and weakness in the Aesthetics business. Analysts recommend holding the stock (Zacks Rank #3) as long-term prospects remain intact with expected 10% revenue growth in 2026. | View source ↗ | Zacks Investment Research | Oct 1, 2026 | bullish | 0.25 | 1 |
| ABBV Stock Rises 25% in 6 Months: Time to Buy, Hold or Sell? | AbbVie's stock has gained 25.4% over six months, driven by strong growth from Skyrizi and Rinvoq, which are expected to generate over $31 billion in combined 2026 sales. The company is successfully navigating Humira's patent expiry through new immunology and neuroscience products. However, challenges include Humira biosimilar erosion, slowing oncology sales, and weakness in the Aesthetics business. Analysts recommend holding the stock (Zacks Rank #3) as long-term prospects remain intact with expected 10% revenue growth in 2026. | View source ↗ | Zacks Investment Research | Oct 1, 2026 | bullish | 0.25 | 1 |
| AbbVie Inc. Stock Grades | ABBV - Barron's | AbbVie Inc. Stock Grades | ABBV Barron's | View source ↗ | Barron's | Sep 29, 2026 | neutral | 0 | 0.6 |
| If You Invested $1000 In AbbVie Stock 10 Years Ago, You Would Have This Much Today - Benzinga | If You Invested $1000 In AbbVie Stock 10 Years Ago, You Would Have This Much Today Benzinga | View source ↗ | Benzinga | Sep 29, 2026 | neutral | 0 | 0.6 |
| AbbVie vs. Johnson & Johnson: Which Healthcare Stock Is a Better Buy in 2026? - The Motley Fool | AbbVie vs. Johnson & Johnson: Which Healthcare Stock Is a Better Buy in 2026? The Motley Fool | View source ↗ | The Motley Fool | Sep 25, 2026 | neutral | 0 | 0.6 |
| Does AbbVie Stock Have More Upside? - Trefis | Does AbbVie Stock Have More Upside? Trefis | View source ↗ | Trefis | Aug 26, 2026 | neutral | 0 | 0.6 |
| How ABBV Stock Moved Away From Its Peer Group - Trefis | How ABBV Stock Moved Away From Its Peer Group Trefis | View source ↗ | Trefis | Aug 12, 2026 | neutral | 0 | 0.6 |
| Why AbbVie (ABBV) Stock Is Up Today | ABBV Stock News - Quiver Quantitative | Why AbbVie (ABBV) Stock Is Up Today | ABBV Stock News Quiver Quantitative | View source ↗ | Quiver Quantitative | Jul 16, 2026 | neutral | 0 | 0.6 |
Informational research only, not financial advice. Forecasts are uncertain and can be wrong.